New Therapeutic Options in Mild Moderate COVID-19 Outpatients.

Ucciferri ClaudioAlessandro Di GasbarroPaola Borrelli Marta Di NicolaJacopo VecchietFalasca Katia

Published in: Microorganisms (2022)

In the first phase of disease, pidotimod can represent an effective, low-cost, weapon, without restrictions of use, that is able to prevent a second aggressive phase and promote faster virological recovery.

Keyphrases

low cost
coronavirus disease
sars cov
hiv infected
high intensity
antiretroviral therapy
hiv infected patients